Caris Life Sciences Authorizes $100 Million Share Repurchase Program
CAI•Caris Life Sciences board approved a stock repurchase program authorized to buy back up to $100 million in common shares with no expiration date. Repurchases may occur via open market or private transactions under Rule 10b5-1 using available cash and cash equivalents at management’s discretion.
1. Board Authorizes $100M Repurchase Program
On June 8, Caris Life Sciences’ board approved a share buyback program permitting repurchase of up to $100 million of common stock with no set expiration date. Purchases may be executed via open market purchases, privately negotiated transactions or through Rule 10b5-1 trading plans.
2. Funding, Timing and Strategic Rationale
The company plans to fund repurchases using available cash and cash equivalents, with timing, price and volume determined by management based on market conditions, stock price, financial performance and capital requirements. The program is designed to optimize capital allocation and enhance shareholder returns.
